Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.

@article{Cortes2005MolecularRI,
  title={Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.},
  author={Jorge E. Cortes and Moshe Talpaz and Susan O'brien and Dan Jones and Rajyalakshmi Luthra and Jenny Shan and Francis J Giles and Stefan H. Faderl and Srdan Verstovsek and Guillermo Garcia-Manero and Mary Beth Rios and Hagop M Kantarjian},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2005},
  volume={11 9},
  pages={
          3425-32
        }
}
PURPOSE To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib. EXPERIMENTAL DESIGN We analyzed the results of quantitative PCR in 280 patients with CML in chronic phase who achieved complete cytogenetic remission with imatinib (117 after IFN-alpha failure and 163 previously untreated). Median follow-up was 31 months (range, 3-52 months). RESULTS Median BCR-ABL/ABL ratio before the start of… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS, ESTIMATED 44% COVERAGE

An In-House Method for Molecular Monitoring of BCR-ABL

  • Turkish journal of haematology : official journal of Turkish Society of Haematology
  • 2011

FILTER CITATIONS BY YEAR

2006
2018

CITATION STATISTICS

  • 1 Highly Influenced Citations